IP Library › Granted Patent US 8,580,766
Granted Patent B2
US 8,580,766 · App. 12/363,265 · Granted Nov 12, 2013

Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,580,766
App. No.
12/363,265
Granted
Nov 12, 2013
Kind
B2
Abstract

The invention provides compositions and methods useful for the treatment and/or prevention of interstitial cystitis and/or a related urinary tract condition in man or in animals. Specifically, provided are compositions specially formulated for direct instillation into the bladder and/or parenteral use in the treatment and/or prevention of interstitial cystitis. Compositions adapted for direct instillation into the bladder and/or for systemic administration are provided comprised of therapeutic amounts of: chondroitin sulfate in combination with hyaluronan (hyaluronic acid) are provided. Compositions adapted for direct instillation into the bladder and/or for systemic administration are also provided comprised of therapeutic amounts of: chondroitin sulfate, hyaluronan (hyaluronic acid) and N-acetyl D-glucosamine.

Claims (15)

1. A composition formulated for direct bladder instillation and for treatment of interstitial cystitis or a related urinary tract condition in man or in animals consisting essentially of from about 0.5 grams to about 1.5 grams per unit dose of the composition of chondroitin sulfate and from about 10 mg to about 50 mg per unit dose of the composition of hyaluronan.

2. The composition of claim 1 , wherein the suitable chondroitin sulfate is CS4 chondroitin sulfate.

3. The composition of claim 1 , wherein the suitable chondroitin sulfate is CS6 chondroitin sulfate.

4. The composition of claim 1 , wherein the suitable chondroitin sulfate is a mixture of CS4 chondroitin sulfate and CS6 chondroitin sulfate.

5. The composition of claim 1 , wherein said composition is a sterile solution.

6. The composition of claim 1 , wherein said composition is a sterile suspension.

7. A method for treatment of interstitial cystitis or a related urinary tract condition in man or in animals, comprising administering directly into the bladder of said man or animals in need thereof a therapeutic amount of the composition of consisting essentially of a therapeutic amount chondroitin sulfate and hyaluran.

8. The method of claim 7 , wherein the composition is administered by direct parenteral instillation into the bladder.

9. The method of claim 7 , wherein the composition comprises between about 0.5 grams to about 1.5 grams of a suitable chondroitin sulfate per unit dose of the composition.

10. The method of claim 9 , wherein the suitable chondroitin sulfate is CS4 chondroitin sulfate.

11. The method of claim 9 , wherein the suitable chondroitin sulfate is CS6 chondroitin sulfate.

12. The method of claim 9 , wherein the suitable chondroitin sulfate is a mixture of CS4 chondroitin sulfate and CS6 chondroitin sulfate.

13. The method of claim 7 , wherein the composition comprises about 10 mg to about 50 mg of hyaluronan per unit dose of the composition.

14. The method of claim 7 , wherein the composition is a sterile solution.

15. The method of claim 7 , wherein the composition is a sterile suspension.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2017
From: ARTHRODYNAMIC TECHNOLOGIES, ANIMAL HEALTH DIVISION, INC.
To: ARTHRODYNAMIC HOLDINGS, LLC
Reel/Frame 040854/0031 →